Printer Friendly

Chelsea Therapeutics receives approval to use Northera capsules from US Food and Drug Administration.

M2 PHARMA-February 20, 2014-Chelsea Therapeutics receives approval to use Northera capsules from US Food and Drug Administration

(C)2014 M2 COMMUNICATIONS

Chelsea Therapeutics (Nasdaq:CHTP), a biopharmaceutical company, has received approval to use Northera capsules (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension, from the United States Food and Drug Administration, it was reported yesterday.

The drug is the first and only therapy approved by the United States Food and Drug Administration that indicated symptomatic benefit in patients with neurogenic orthostatic hypotension.

The United States Food and Drug Administration is approving the drug under the accelerated approval programme, which enables for conditional approval of a drug to treat a serious disease based on clinical data showing that the drug has an effect on an intermediate clinical measure.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 20, 2014
Words:139
Previous Article:DKSH Business Unit Healthcare signs regional agreement with Cheplapharm.
Next Article:MicroBiome reports top-line results from clinical trial of microbiome modulator NM504.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters